EMR
57
7
KLAC
45
3
FAST
41
7
CSCO
63
5
CAT
47
3
MKC
54
3
V
70
14
TAP
57
6
LNC
28
3
NTAP
58
3
MTCH
62
22
GE
60
5
TGT
35
4
GME
61
2
LH
33
3
MSI
52
3
MDT
59
4
ECL
54
5
AAPL
64
3
EFX
43
3
EMR
57
7
KLAC
45
3
FAST
41
7
CSCO
63
5
CAT
47
3
MKC
54
3
V
70
14
TAP
57
6
LNC
28
3
NTAP
58
3
MTCH
62
22
GE
60
5
TGT
35
4
GME
61
2
LH
33
3
MSI
52
3
MDT
59
4
ECL
54
5
AAPL
64
3
EFX
43
3
Financhill
Back

Melexis NV 10K Form

Sell
31

MLXSF
Melexis NV

Last Price:
$74.25
Seasonality Move:
-2.89%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MLXSF News And Ratings

See the #1 stock for the next 7 days that we like better than MLXSF

MLXSF Financial Statistics

Sales & Book Value

Annual Sales: $1B
Cash Flow: $41M
Price / Cash Flow: 26.95
Annual Sales: $16.72
Price / Book: 4.44

Profitability

EPS (TTM): 5.45210
Net Income (TTM): $220.3M
Gross Margin: $476.6M
Return on Equity: 35.37%
Return on Assets: 23.31%

Melexis NV Earnings Forecast

Key Melexis NV Financial Ratios

  • The Gross Profit Margin over the past 22 years for MLXSF is 45.65%.
  • The Selling, General & Administrative Expenses for MLXSF have been equal to 3.40% of Gross Profit Margin.
  • The Research & Development expenses have been 11.07% of Revenue.
  • The Interest Expense is 2.86% of Operating Income.
  • The Net Earning history of MLXSF is 21.72% of Total Revenues.
  • Per Share Earnings over the last 22 years have been positive in 15 years.

Melexis NV Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Semiconductors & Semiconductor Equipment
Sector: Information Technology
Current Symbol: MLXSF
Website: melexis.com

Debt

Debt-to-Equity Ratio: 0.31
Current Ratio: 5.12
Quick Ratio: 1.93

Price-to-Earnings

Trailing P/E Ratio: 13.24
Forward P/E Ratio: 0

MLXSF Technical Analysis vs Fundamental Analysis

Sell
31
Melexis NV (MLXSF) is a Sell

Is Melexis NV a Buy or a Sell?

  • Melexis NV stock is rated a Sell
    The current Melexis NV [MLXSF] share price is $74.25. The Score for MLXSF is 31, which is 38% below its historic median score of 50, and infers higher risk than normal.